{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:11:16Z","timestamp":1753888276900,"version":"3.41.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Adrenocortical carcinoma is an orphan but aggressive malignancy with limited treatment options. Cabozantinib (CAB), a tyrosine kinase inhibitor, has emerged as a new potential treatment. However, no data are available on whether and how CAB can be administered to patients undergoing hemodialysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>An liquid chromatography with tandem mass spectrometry detection method was developed and validated according to the European Medicines Agency and United States Food and Drug Administration guidelines for bioanalytical method validation. The samples were prepared using protein precipitation and online solid-phase extraction. The method was applied to clinical samples of an adrenocortical carcinoma patient receiving CAB treatment (80 mg daily). During the 10 days of observation, the patient received periodic hemodialysis on 7 days. Pharmacokinetic (PK) simulations were performed using Bayesian forecasting according to an existing population PK model for CAB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Based on the PK simulation, a mean plasma trough concentration of 1375 ng\/mL [90% prediction interval (PI), 601\u20132602 ng\/mL] in the steady state at a daily dose of 80 mg was expected for CAB. However, an individual simulation involving the measured plasma levels of the patient resulted in a mean trough concentration of 348 ng\/mL (90% PI, 278\u2013430 ng\/mL). The model based on individual PK parameters estimated accessible plasma levels of 521, 625, and 834 ng\/mL by dose adjustment to 100, 120, and 160 mg, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>After establishing an liquid chromatography with tandem mass spectrometry detection method for therapeutic drug monitoring of CAB, our analyses involving a single patient undergoing hemodialysis indicated that higher than expected doses of CAB were required to achieve reasonable plasma concentrations. Our study demonstrates the usefulness of therapeutic drug monitoring for the evaluation of \u201cnew\u201d drugs in patients with renal impairment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000905","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T07:02:16Z","timestamp":1621321336000},"page":"706-711","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis"],"prefix":"10.1097","volume":"43","author":[{"given":"Sebastian","family":"Zimmermann","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Institute for Pharmacy and Food Chemistry, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Kurlbaum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology\/Diabetology, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany. Dr. Kroiss is now with the Department of Medicine IV, University Hospital Munich, Ludwig- Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany;"},{"name":"Core Unit Clinical Mass Spectrometry, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Nephrology, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology\/Diabetology, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany. Dr. Kroiss is now with the Department of Medicine IV, University Hospital Munich, Ludwig- Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany;"},{"name":"Comprehensive Cancer Center Mainfranken, University of W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology\/Diabetology, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany. Dr. Kroiss is now with the Department of Medicine IV, University Hospital Munich, Ludwig- Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany;"},{"name":"Core Unit Clinical Mass Spectrometry, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"},{"name":"Comprehensive Cancer Center Mainfranken, University of W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Institute for Pharmacy and Food Chemistry, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma. Multicenter study research support, non-U.S. Gov't","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol."},{"issue":"18_suppl","key":"R12-20250603","doi-asserted-by":"crossref","first-page":"15527","DOI":"10.1200\/jco.2007.25.18_suppl.15527","article-title":"A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC)","volume":"25","author":"Samnotra","year":"2007","journal-title":"J Clin Oncol."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"dgz318","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1078-0432.CCR-16-1073","article-title":"U.S. Food and drug administration approval: cabozantinib for the treatment of advanced renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin Cancer Res."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1158\/0008-5472.CAN-14-3707","article-title":"Hepatocyte growth factor\/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma","volume":"75","author":"Phan","year":"2015","journal-title":"Cancer Res."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.MCT-14-0094","article-title":"Combination strategy targeting VEGF and HGF\/c-met in human renal cell carcinoma models","volume":"14","author":"Ciamporcero","year":"2015","journal-title":"Mol Cancer Ther."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1124\/dmd.115.063610","article-title":"Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites","volume":"43","author":"Lacy","year":"2015","journal-title":"Drug Metab Dispos."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol (Oxf)."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br J Clin Pharmacol."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two\u2013targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"e4758","DOI":"10.1002\/bmc.4758","article-title":"Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS\/MS","volume":"34","author":"Krens","year":"2020","journal-title":"Biomed Chromatogr."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/jcph.1467","article-title":"Updated population pharmacokinetic model of cabozantinib integrating various cancer types including hepatocellular carcinoma","volume":"59","author":"Nguyen","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1746-1596-9-19","article-title":"Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status","volume":"9","author":"Zhang","year":"2014","journal-title":"Diagn Pathol."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jcph.510","article-title":"Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK","volume":"55","author":"Nguyen","year":"2015","journal-title":"J Clin Pharmacol."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1099736","article-title":"Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone","volume":"305","author":"Williams","year":"2004","journal-title":"Science"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0090-9556(24)15008-8","article-title":"Effect of the adrenal 11-\u03b2-Hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4","volume":"28","author":"Harvey","year":"2000","journal-title":"Drug Metab Dispos."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/pcmr.12557","article-title":"Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis","volume":"30","author":"Park","year":"2017","journal-title":"Pigment Cel Melanoma Res"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:18Z","timestamp":1748970858000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000905","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"2021-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}